IntrinsicIntrinsic
← All summaries

ADIAL PHARMACEUTICALS, INC.

ADIL
Financials & Chart →

Business Summary

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for addiction and related disorders, with its primary investigational new drug candidate, AD04, targeting alcohol use disorder (AUD) in patients with specific genetic profiles . The company has incurred net losses since its inception, including approximately $8.0 million for the year ended December 31, 2025, and approximately $13.2 million for the year ended December 31, 2024, with accumulated deficits of approximately $90.0 million and $82.0 million as of December 31, 2025 and 2024, respectively. The company currently has no products approved for sale and has not generated significant revenue, funding its operations primarily through private and public placements of debt, equity securities, and an equity line .

The core business model revolves around the development and eventual commercialization of AD04, which is ondansetron formulated at a much lower concentration (0.33mg per tablet) than generic versions, and is intended for use with a companion diagnostic genetic test to identify patients with specific polymorphisms in the serotonin transporter and receptor genes . This approach aims to provide a patient-centered treatment for AUD that supports harm reduction, allowing patients to reduce heavy drinking without requiring complete abstinence, and is orally administered, currently twice daily, with a once-daily formulation planned for lifecycle management . The companion diagnostic genetic test is designed to enhance treatment outcomes by providing clinicians with a structured way to discuss alcohol use and identify patients most likely to benefit, thereby potentially increasing AD04's use .

The company's product and service line is centered on AD04 for AUD, specifically targeting patients carrying the HTR3A rs1150226 AG genotype and the combined HTR3A/HTR3B variant pattern characterized by the presence of both the AG (HTR3A) and AC (HTR3B rs1176744) alleles . These biomarker-positive genotypes represent the populations most likely to benefit from AD04 based on prior clinical and mechanistic evidence . The company plans to develop label expansions into other indications such as opioid use disorder, other drug addictions, obesity, smoking cessation, and eating disorders in the longer term .

For the fiscal year ended December 31, 2025, the company reported total operating expenses of $7,799,462 , resulting in a loss from operations of $(7,799,462) . Net loss for the period was $(7,977,171) , leading to a basic and diluted loss per share of $(11.93) based on 668,630 weighted average shares outstanding. Cash and cash equivalents stood at $5,881,217 as of December 31, 2025. The company's total liabilities were $1,396,909 , and total stockholders' equity was $5,276,458 .

Comparing year-over-year, research and development expenses decreased by approximately $609,000 , or 19% , from $3,229,000 in 2024 to $2,620,000 in 2025, primarily due to decreased clinical activity and lower compensation expense . General and administrative expenses increased by approximately $125,000 , or 2% , from $5,055,000 in 2024 to $5,180,000 in 2025, mainly due to higher compensation expense . The net loss decreased from $(13,197,451) in 2024 to $(7,977,171) in 2025, a reduction of $(5,219,000) . Net cash used in operating activities decreased by approximately $429,000 in 2025 compared to 2024, primarily due to the decrease in net loss excluding inducement expense . Net cash provided by financing activities increased by approximately $627,000 in 2025, reaching $8,473,295 from $7,845,749 in 2024, driven by warrant exercises and stock sales .

Significant operational developments during the period include the entry into a collaboration framework agreement with Molteni Farmaceutici on March 3, 2026, for a proposed exclusive partnership covering the commercialization of AD04 in Europe, which is expected to include an upfront payment, milestone payments, and tiered royalties with a total potential aggregate value estimated at nearly $60 million . The company also announced the receipt of final meeting minutes from its End of Phase 2 (EOP2) meeting with the FDA on September 16, 2025, where the FDA provided formal input on the AD04 Phase 3 adaptive clinical trial design and broader clinical development strategy, including alignment on target population, clinical endpoints, and affirmation of biomarker-positive and biomarker-negative groups . An independent statistical review reanalyzed ONWARD data, validating the predictive value of HTR3A and HTR3B SNPs and reinforcing their role in treatment stratification . The company filed a new patent in 2025, which, if granted, would extend patent protection of AD04 to 2045 .

Business Outlook

Management's current planning assumption is to conduct one Phase 3 trial with an adaptive enrichment trial design, one subsequent confirmatory Phase 3 trial, and one open label extension safety study for AD04 . However, based on a recent article published on February 19, 2026, in The New England Journal of Medicine, FDA leadership has outlined a shift in evidentiary posture where approval may be supported by one adequate and well-controlled clinical investigation plus confirmatory evidence, rather than two independent pivotal studies . If AD04 can be advanced under a one-study framework, it could substantially lower Phase 3 costs, improve capital efficiency, and accelerate the path toward NDA submission . The FDA has confirmed that a comparison of the percentage of patients with no heavy drinking days in the last two months of a six-month clinical trial between the drug and placebo groups will be a satisfactory primary endpoint for a successful Phase 3 trial of AD04 .

A major growth area for the company is the advancement of the AD04 clinical development program in the US, with plans to pursue FDA approval for alcohol use disorder in genetically targeted populations . The company believes there is a clear, cost-effective path toward FDA approval based on detailed analysis of prior Phase 2 and the ONWARD Phase 3 clinical trials, which identified two specific genotypes (HTR3A rs1150226 AG genotype and the combined HTR3A/HTR3B variant pattern with AG (HTR3A) and AC (HTR3B rs1176744) alleles) that are believed to meet the FDA's prespecified primary endpoint of zero heavy drinking days in months five and six . Market research suggests that unit pricing for AD04 could be significantly higher than previous assumptions, confirming it as an attractive commercial opportunity . The company intends to engage a U.S. partner to assist with funding anticipated clinical trials and commercialization efforts, aiming for rapid market penetration given expectations of wide accessibility, reasonable pricing, and reimbursability .

Another growth vector is the proposed exclusive partnership with Molteni Farmaceutici for the commercialization of AD04 in Europe . This collaboration framework, subject to a definitive agreement, outlines strategic and financial parameters covering clinical, regulatory, manufacturing, and commercial terms . The definitive agreement is expected to include an upfront payment, milestone payments tied to development and commercial progress, and tiered royalties on European AD04 net sales, with the total potential aggregate value from royalties and milestones estimated at nearly $60 million , assuming successful clinical development and market introduction in Europe .

Operationally, the company plans to comply with ICH E1A by adding a long-term safety follow-up to the planned Phase 3 trial, exposing at least 100 patients to AD04 for one year . The FDA has agreed that a thorough QT study will not be required . In parallel with Phase 3 trials, standard Phase 1 studies may be conducted to assess potentiation of alcohol's central nervous system effects and pharmacodynamic impact of certain cytochrome P450 enzyme variants . The company has signed a contract with a vendor for approximately $2.3 million , with approximately $1.9 million remaining, to produce sufficient drug product, validate manufacturing processes, and manufacture registration batches for commercial usage .

The company's current cash and cash equivalents of $5.9 million are expected to fund operations into the second half of 2026 . Additional financing will be required to execute the overall business strategy, including the planned Phase 3 trials . The company is actively pursuing financing and other strategic plans, including equity and/or debt financings, grant funding, strategic relationships, or out-licensing .

Structural headwinds and execution risks include the uncertainty of securing additional financing on acceptable terms, which could lead to delays, scaling back, or elimination of research and development programs . The company's ability to sell shares under the AGP ATM is restricted by SEC rules, and under the ELOC Agreement by its terms and Nasdaq rules . There is no assurance that a definitive agreement with Molteni will be executed, or that AD04 will successfully progress through clinical development and commercialization in Europe, or that any royalties or milestone payments will be received . The success of AD04 is also dependent on the successful development, approval, and commercialization of a genetic test, which is expected to be classified as a companion diagnostic . The FDA has indicated that some research in genotype-negative patients may be required prior to approval of AD04 for AUD within that population, and that clinical trials conducted with only genotype-positive subjects will likely result in labeling restricted to treating genotype-positive patients .

Risk Factors

The company faces substantial doubt about its ability to continue as a going concern, having incurred net losses of approximately $8.0 million in 2025 and used cash in operations of approximately $6.5 million , with current cash and cash equivalents not expected to fund operations for the next twelve months . There is a significant risk that additional financing may not be available on favorable terms or at all, which could force delays or elimination of research and development programs . The success of AD04 is dependent on regulatory approval, which requires extensive and expensive clinical testing, with no guarantee that Phase 2 results will be replicated in additional pivotal Phase 3 studies or that the FDA will accept planned endpoints . The active ingredient, ondansetron, is available generically, posing a risk of off-label use at higher doses that lack demonstrated efficacy for AUD and carry safety concerns, including cardiovascular side effects at higher doses . The company relies on an exclusive license from UVA LVG, which could be terminated if diligence milestones, such as submitting an NDA by March 31, 2028 and commencing commercialization by March 31, 2029 , are not met, halting the ability to market products . Rapid technological change and substantial competition from better-funded pharmaceutical and biotechnology companies, universities, and governmental entities could render AD04 noncompetitive . International operations expose the company to differing regulatory and reimbursement requirements, economic instability, foreign currency fluctuations, and challenges in enforcing intellectual property rights . Cybersecurity threats, including potential breaches of information technology systems, could lead to data loss, litigation, regulatory penalties, and reputational harm . Furthermore, the company's common stock has been thinly traded and volatile, with a closing price of $1.99 on March 4, 2026, and $5.50 on December 31, 2025, and future sales of securities could result in additional dilution .

Management Priorities

Management's message to shareholders emphasizes a focused strategy on advancing AD04 towards regulatory approval for alcohol use disorder in the United States, the European Union, and other territories, with subsequent plans for label expansions into other addiction-related indications . They highlight a clear, cost-effective path toward FDA approval based on detailed analysis of prior clinical trials and positive regulatory feedback, particularly on the primary endpoint of reducing heavy drinking days to zero . Management is actively pursuing financing and strategic partnerships, including the recently announced collaboration framework agreement with Molteni Farmaceutici for European commercialization, which is expected to yield significant royalties and milestone payments . They also stress the importance of prosecuting and expanding the company's intellectual property estate, including a new patent filed in 2025 that could extend protection to 2045 , and managing the business with efficiency and discipline to minimize capital requirements and expedite product development .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 7, MD&A — Overview
  3. [3] Item 7, MD&A — Overview
  4. [4] Item 7, MD&A — Overview
  5. [5] Item 7, MD&A — Overview
  6. [6] Item 1, Business — Overview
  7. [7] Item 1, Business — Our Proposed Solution is AD04 and a PGx Companion Diagnostic
  8. [8] Item 1, Business — Our Proposed Solution is AD04 and a PGx Companion Diagnostic
  9. [9] Item 1, Business — Our Proposed Solution is AD04 and a PGx Companion Diagnostic
  10. [10] Item 1, Business — Companion Genetic Bio-Marker Test Aimed at Identifying Patients Most Likely to Respond To Treatment, Potentially Results in Increased Use of AD04
  11. [11] Item 1, Business — Strengths and Competitive Advantages
  12. [12] Item 1, Business — Strengths and Competitive Advantages
  13. [13] Item 1, Business — Our Strategy for AD04 and Addiction Related Diseases and Disorders
  14. [14] Item 7, MD&A — Results of Operations for the Years Ended December 31, 2025 and 2024
  15. [15] Item 7, MD&A — Results of Operations for the Years Ended December 31, 2025 and 2024
  16. [16] Item 7, MD&A — Results of Operations for the Years Ended December 31, 2025 and 2024
  17. [17] Item 7, MD&A — Results of Operations for the Years Ended December 31, 2025 and 2024
  18. [18] Item 7, MD&A — Results of Operations for the Years Ended December 31, 2025 and 2024
  19. [19] Item 7, MD&A — Liquidity and Capital Resources
  20. [20] Item 8, Consolidated Balance Sheets
  21. [21] Item 8, Consolidated Balance Sheets
  22. [22] Item 7, MD&A — Research and development ("R&D") expenses
  23. [23] Item 7, MD&A — Research and development ("R&D") expenses
  24. [24] Item 7, MD&A — Research and development ("R&D") expenses
  25. [25] Item 7, MD&A — Research and development ("R&D") expenses
  26. [26] Item 7, MD&A — Research and development ("R&D") expenses
  27. [27] Item 7, MD&A — General and administrative expenses ("G&A") expenses
  28. [28] Item 7, MD&A — General and administrative expenses ("G&A") expenses
  29. [29] Item 7, MD&A — General and administrative expenses ("G&A") expenses
  30. [30] Item 7, MD&A — General and administrative expenses ("G&A") expenses
  31. [31] Item 7, MD&A — General and administrative expenses ("G&A") expenses
  32. [32] Item 7, MD&A — Results of Operations for the Years Ended December 31, 2025 and 2024
  33. [33] Item 7, MD&A — Results of Operations for the Years Ended December 31, 2025 and 2024
  34. [34] Item 7, MD&A — Results of Operations for the Years Ended December 31, 2025 and 2024
  35. [35] Item 7, MD&A — Net cash used in operating activities
  36. [36] Item 7, MD&A — Net cash used in operating activities
  37. [37] Item 7, MD&A — Net cash provided by financing activities
  38. [38] Item 7, MD&A — Net cash provided by financing activities
  39. [39] Item 7, MD&A — Net cash provided by financing activities
  40. [40] Item 7, MD&A — Net cash provided by financing activities
  41. [41] Item 1, Business — Recent Developments
  42. [42] Item 1, Business — Recent Developments
  43. [43] Item 1, Business — U.S. Clinical Development and Regulatory Actions Completed
  44. [44] Item 1, Business — Our Substantial Proprietary Intellectual Property Estate and Protection from Competition
  45. [45] Item 7, MD&A — Clinical Trials — Research and Development Schedule
  46. [46] Item 7, MD&A — Clinical Trials — Research and Development Schedule
  47. [47] Item 1, Business — U.S. Clinical Development and Regulatory Actions Planned
  48. [48] Item 7, MD&A — Clinical and Research Developments
  49. [49] Item 1, Business — Near Term
  50. [50] Item 1, Business — Near Term
  51. [51] Item 1, Business — Near Term
  52. [52] Item 1, Business — Near Term
  53. [53] Item 1, Business — Recent Developments
  54. [54] Item 1, Business — Recent Developments
  55. [55] Item 1, Business — Recent Developments
  56. [56] Item 1, Business — Recent Developments
  57. [57] Item 7, MD&A — Safety Requirements
  58. [58] Item 7, MD&A — Safety Requirements
  59. [59] Item 7, MD&A — Safety Requirements
  60. [60] Item 7, MD&A — Liquidity and Capital Resources
  61. [61] Item 7, MD&A — Liquidity and Capital Resources
  62. [62] Item 7, MD&A — Liquidity and Capital Resources
  63. [63] Item 7, MD&A — Liquidity and Capital Resources
  64. [64] Item 7, MD&A — Liquidity and Capital Resources
  65. [65] Item 7, MD&A — Liquidity and Capital Resources
  66. [66] Item 7, MD&A — Liquidity and Capital Resources
  67. [67] Item 7, MD&A — Liquidity and Capital Resources
  68. [68] Item 7, MD&A — Liquidity and Capital Resources
  69. [69] Item 1, Business — Recent Developments
  70. [70] Item 1A, Risk Factors — Our investigational product, AD04, is dependent on a successful development, approval, and commercialization of a genetic test, which is expected to be classified as a companion diagnostic.
  71. [71] Item 1A, Risk Factors — We will incur additional costs and our approvals could be delayed if the FDA or other global regulators requires additional clinical trials in patients that are negative for the genotypes targeted by AD04.
  72. [72] Item 1A, Risk Factors — We have incurred net losses every year and quarter since our inception and anticipate that we will continue to incur net losses in the future.
  73. [73] Item 1A, Risk Factors — Our independent registered public accounting firm has expressed doubt about our ability to continue as a going concern.
  74. [74] Item 1A, Risk Factors — We will need to secure additional financing in order to support our operations and fund our current and future clinical trials.
  75. [75] Item 1A, Risk Factors — We will need to secure additional financing in order to support our operations and fund our current and future clinical trials.
  76. [76] Item 1A, Risk Factors — The current data for our lead product candidate, AD04 are the result of Phase 2 clinical trials conducted by third parties as well as data generated from the ONWARD trial we conducted and do not currently provide sufficient evidence that our products are viable as potential pharmaceutical products.
  77. [77] Item 1A, Risk Factors — The active ingredient of our product candidate, ondansetron, is currently available in generic form.
  78. [78] Item 1A, Risk Factors — We rely on a license to use various technologies that are material to our business and if the agreement were to be terminated or if other rights that may be necessary or we deem advisable for commercializing our intended products cannot be obtained, it would halt our ability to market our products and technology, as well as have an immediate material adverse effect on our business, operating results and financial condition.
  79. [79] Item 1A, Risk Factors — We rely on a license to use various technologies that are material to our business and if the agreement were to be terminated or if other rights that may be necessary or we deem advisable for commercializing our intended products cannot be obtained, it would halt our ability to market our products and technology, as well as have an immediate material adverse effect on our business, operating results and financial condition.
  80. [80] Item 1A, Risk Factors — We rely on a license to use various technologies that are material to our business and if the agreement were to be terminated or if other rights that may be necessary or we deem advisable for commercializing our intended products cannot be obtained, it would halt our ability to market our products and technology, as well as have an immediate material adverse effect on our business, operating results and financial condition.
  81. [81] Item 1A, Risk Factors — Rapid technological change and substantial competition may impair the business.
  82. [82] Item 1A, Risk Factors — A variety of risks associated with marketing AD04 or any future product candidates internationally could materially adversely affect our business.
  83. [83] Item 1A, Risk Factors — Any failure to maintain the security of information relating to our patients, customers, employees and suppliers, whether as a result of cybersecurity attacks or otherwise, could expose us to litigation, government enforcement actions and costly response measures, and could disrupt our operations and harm our reputation.
  84. [84] Item 1A, Risk Factors — Our stock price has fluctuated in the past, has recently been volatile and may be volatile in the future, and as a result, investors in our common stock could incur substantial losses.
  85. [85] Item 1A, Risk Factors — Our stock price has fluctuated in the past, has recently been volatile and may be volatile in the future, and as a result, investors in our common stock could incur substantial losses.
  86. [86] Item 1A, Risk Factors — Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans and outstanding warrants, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
  87. [87] Item 1, Business — Our Strategy for AD04 and Addiction Related Diseases and Disorders
  88. [88] Item 1, Business — Near Term
  89. [89] Item 1, Business — Recent Developments
  90. [90] Item 1, Business — Our Substantial Proprietary Intellectual Property Estate and Protection from Competition
  91. [91] Item 1, Business — Near Term

Analysis on 5/19/2026